Jaguar, Filament Team Up To Develop Botanical Drugs For Mental Health Disorders

Filament Health Announces FDA Authorization Of Phase 2 Clinical Trial Studying PEX010, The Company's Botanical Psilocybin Drug Candidate, In Opioid Use Disorder

Filament Health Announces Private Placement And Intention To Voluntarily Delist From Cboe Canada

Filament Health Reports Q4 And Year End 2024 Financial Results And Operational Highlights